Update on salvage options in relapsed/refractory hodgkin lymphoma after autotransplant.

摘要: Despite a high clinical success, relapse in Hodgkin lymphoma occurs 10–30% of cases and 5–10% patients are nonresponsive to initial chemotherapy. The standard management these includes high-dose chemotherapy followed by autologous stem cell transplant. However, 50% ultimately after autotransplant which poses big challenge. Allogeneic transplantation offers the only chance cure patients. For who not candidates for allogeneic transplantation, achieving with other possible options is highly unlikely, thus treatment plan becomes noncurative. Various novel agents have shown promising results but duration response short lived. A approach deliver most effective still lacking. This review focuses on currently available relapsed refractory disease autotransplant.